Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
TMO reports a planned sale of 4,883 shares of common stock through Fidelity Brokerage Services on the NYSE on 08/07/2026, with an aggregate market value of $2,822,374.00. These shares consist of 4,608 from restricted stock vesting dated 02/15/2013 and 275 from a stock option exercise on 08/07/2026. The issuer reports 369,747,286 common shares outstanding. In the prior three months, entities including Floral Park Associates Inc. and Marc N. Casper completed multiple common stock sales ranging from 5,000 to 10,000 shares per transaction.
Thermo Fisher Scientific’s affiliate filed to permit the public resale of 15,000 shares of common stock on the NYSE, with an aggregate market value of $8,652,000.00 and 369,747,286 common shares outstanding as of August 6, 2026.
The shares derive from a planned 10,000-share stock option exercise on August 6, 2026 and 5,000 shares from restricted stock vesting events in 2013 and 2015. Over the prior three months, Floral Park Associates Inc. sold 5,000 shares for $2,876,145.43 and Marc N. Casper sold 10,000 shares for $5,752,296.00.
An affiliate of the issuer with symbol TMO has notified an intention to sell up to 15,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate market value of $8,518,950.00 as of 08/05/2026.
The shares derive from 5,000 shares acquired via restricted stock vesting on 02/26/2015 as compensation and 10,000 shares to be acquired through a stock option exercise for cash on 08/05/2026. The issuer reports 369,747,286 common shares outstanding, which is a baseline figure, not the amount being sold.
Thermo Fisher Scientific Inc. reported Q2 2026 revenue of $11,994 million, up 10% year over year (5% organic). GAAP operating income rose to $2,087 million with a 17.4% margin, while adjusted operating income reached $2,735 million with a 22.8% margin. GAAP diluted EPS was $4.68, up 9%, and adjusted EPS $6.03, up 13%.
Growth was broad-based: Laboratory Products and Biopharma Services revenue increased 12%, Life Sciences Solutions 13%, Analytical Instruments 7% and Specialty Diagnostics 6%, all with margin expansion supported by productivity initiatives. Remaining performance obligations totaled $29.70 billion, about 52% expected to convert to revenue within 12 months.
For the first six months of 2026, cash from operations was $3,317 million and free cash flow $2,503 million. The company used $8,872 million on acquisitions, mainly the $9,098 million Clario Holdings purchase, and $4,000 million on share repurchases, reducing cash to $4,064 million and increasing total debt to $42,549 million. It agreed to sell its microbiology business for approximately $1.075 billion and recorded $147 million of restructuring and other costs year to date, with additional charges of about $220 million expected, primarily in 2026.
Thermo Fisher Scientific Inc. President & COO Gianluca Pettiti sold 400 shares of Common Stock on July 27, 2026 at $565.00 per share in an open-market or private transaction. The sale was effected under a Rule 10b5-1 trading plan adopted on September 12, 2025, and left him with 24,650.832 directly owned shares.
Thermo Fisher Scientific Inc. is the issuer for a planned sale of 400 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated aggregate value of $226,000.00 and a stated date of 07/27/2026. The securities to be sold arise from restricted stock vesting awards dated 02/23/2024 (385 shares) and 02/28/2024 (15 shares), both received from the issuer as compensation. The filing also notes that Gianluca Pettiti sold 400 shares of common stock on 04/27/2026 for an aggregate amount of $185,064.00 during the past three months.
Thermo Fisher Scientific Inc. insider trading plan: Reporting person Gianluca Pettiti filed to potentially sell 400 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated value of $226,000.00. Prior equity acquisitions included 385 and 15 common shares from restricted stock vesting as compensation on February 23, 2024 and February 28, 2024.
Thermo Fisher Scientific reported second quarter 2026 results, with revenue of $11.99 billion, up 10% including 5% organic growth. GAAP diluted EPS was $4.68, up 9%, and adjusted EPS was $6.03, up 13%. GAAP operating income reached $2.09 billion with a 17.4% margin, while adjusted operating income was $2.73 billion with a 22.8% margin. Free cash flow for the quarter was $1,678 million.
Management highlighted stronger end-market demand and several strategic initiatives, including next-generation Orbitrap mass spectrometry platforms, the Applied Biosystems PowerFlex Thermal Cycler, and a flagship U.S. Bioprocess Design Center in Plainville, Massachusetts. The company announced a divestiture of its microbiology business and repurchased $1.0 billion of stock in the quarter. For the first half of 2026, revenue was $22,999 million with 8% growth and organic growth of 3%; GAAP diluted EPS was $9.10 and adjusted EPS was $11.47. Updated 2026 guidance will be discussed on the earnings call.
SPERLING SCOTT M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Scott M. Sperling received a routine equity-based compensation award. He was granted 82.84 Phantom Stock Units on June 27, 2026 under the company’s Deferred Compensation Plan for Directors.
These units are credited at a price of $513.03 per unit and are convertible into Common Stock on a 1-for-1 basis. Following this grant, Sperling holds a total of 17,674.64 Phantom Stock Units. The stock units are scheduled to be distributed in shares of Common Stock when his board service ends for any reason or upon a change of control.